Home › Enlarged Prostate (BPH) › NCT06224218
Prostate Single Port & Laser Enucleation Comparison Trial
Randomized Controlled Trial Comparing Single Port Simple Prostatectomy and Laser Enucleation of the Prostate for Benign Prostatic Hyperplasia
Who can join
Ages 18 to 88 · Men
Full eligibility criteria
Inclusion Criteria: * Patients diagnosed with symptomatic Benign Prostatic Hyperplasia (BPH) who fail conservative treatment with drug therapy are eligible for surgical intervention. Exclusion Criteria: * Adults unable to consent Prisoners Cognitive impaired adults Coagulopathy
About the study
Surgical treatments for benign prostatic hyperplasia (BPH) are necessary when non-procedural approaches fail to alleviate lower urinary tract symptoms (LUTS) or bladder outlet obstruction (BOO). Open simple prostatectomy and laser enucleation are recommended for prostatic adenoma size greater than 80 ml. Minimally invasive approaches, such as robotic-assisted simple prostatectomy, have gained popularity due to their comparable outcomes with lower morbidity. The introduction of the da Vinci single-port (SP) robotic platform offers potential advantages, but its outcomes have not been thoroughly investigated.
This randomized controlled trial aims to compare the outcomes of SP simple prostatectomy performed using the da Vinci robotic platform versus thulium laser enucleation of the prostate for the treatment of BPH and BOO.
What is being tested
- Single Port Robotic Surgery (procedure)
- Laser Surgery (procedure)
Sponsor: University of Illinois at Chicago · Participants: 116 · Started: Jan 15, 2024
Contact the study team
- Ruben Sauer, MD · Phone: 3124135288
Official record on ClinicalTrials.gov — NCT06224218
Locations in the U.S.
| Illinois | UI Health SCB Clinic Department of Urology, Chicago |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.